A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma

Neuroblastoma (NB) is a malignant tumor of the sympathetic nervous system.Chemotherapy and autologous hematopoietic stem cell transplantation are the main treatments for neuroblastoma, and the prognosis of patients with high-risk recurrence and refractory treatment is very poor. There is a large unmet medical need in patients with relapsed refractory neuroblastoma, and further research into new therapeutic approaches is needed for these patients.GD2 is a dissialic ganglioside expressed by neuroectodermal tumors. The proportion of GD2 expression in neuroblastoma is up to 100%, so GD2 is a specific target for neuroblastoma immunotherapy and an ideal target for CAR-T treatment of neuroblastoma.

NCT Number	NCT06684639
Lead Sponsor	The General Hospital of Western Theater Command Collaborators: Yake Biotechnology Ltd.
Conditions	Neuroblastoma
Enrollment	30 participants
Start Date	2024-12-01
Primary Completion	2029-12-01 (estimated)
Study Completion	2030-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-12-20